Aurora Cannabis Inc. was incorporated under the Business Corporations Act of British Columbia on December 21 2006 as Milk Capital Corp and changed its name to Aurora Cannabis Inc on October 2 2014. The company is headquartered in Edmonton Alberta with its registered office in Vancouver British Columbia. Aurora Cannabis Inc. produces distributes and sells cannabis and cannabis derivative products in Canada and in international markets and also engages in the propagation of…
Aurora Cannabis Inc. was incorporated under the Business Corporations Act of British Columbia on December 21 2006 as Milk Capital Corp and changed its name to Aurora Cannabis Inc on October 2 2014. The company is headquartered in Edmonton Alberta with its registered office in Vancouver British Columbia. Aurora Cannabis Inc. produces distributes and sells cannabis and cannabis derivative products in Canada and in international markets and also engages in the propagation of vegetables and floral plants. Its shares trade on the Nasdaq Capital Market and the Toronto Stock Exchange under the ticker ACB and on the Frankfurt Stock Exchange under 21P. The company operates cultivation facilities in several Canadian provinces and maintains production sites in Europe to serve its international medical customers.
Aurora Cannabis Inc. generates revenue primarily from the sale of medical cannabis products to patients and from the sale of adult use cannabis products to recreational consumers in Canada. The company also sells cannabis derivatives such as oils and capsules in its medical markets. Revenue is derived from a direct to patient sales channel in Canada that does not rely on provincial wholesalers or private retailers and allows the company to achieve sustainable gross profit margins better than 60 percent. In international markets Aurora Cannabis Inc. sells medical cannabis through distribution agreements in Germany the United Kingdom Poland and Australia. Additionally Aurora Cannabis Inc. earns income from the propagation and sale of vegetables and floral plants and from licensing its proprietary genetics and breeding outcomes to third parties. The company’s revenue also includes proceeds from the sale of cannabis derived products in its international medical segments.
The company operates through the following segments.
• The Medical Cannabis segment focuses on the production distribution and sale of pharmaceutical grade cannabis products to patients in Canada Germany the United Kingdom Poland and Australia using a direct to patient sales model that does not rely on provincial wholesalers or private retailers and adheres to European Union Good Manufacturing Practices standards. The segment benefits from the company’s regulatory expertise across multiple jurisdictions and its ability to export cannabis that meets strict quality requirements. In Germany Aurora is one of three active in country producers of medical cannabis holding a production and research and development license under the German cannabis law. The company’s Australian operations are conducted through its subsidiary MedReleaf Australia which distributes medical cannabis products in Australia and has expanded sales into New Zealand.
• The Consumer Cannabis segment produces and sells adult use cannabis products in the Canadian market emphasizing high THC and terpene levels and distinctive consumer experiences supported by the company’s genetics and breeding program. The segment focuses on high potency flower varieties that have been developed through the company’s indoor cultivation techniques and post harvest processing improvements. These efforts have reduced per unit production costs by thirty percent or more compared with legacy cultivars. Aurora continues to expand its consumer portfolio by introducing new cultivars such as Cosmic Cream Pink Diesel Chemango Kush and Black Jelly into additional markets worldwide at increasing potency.
• The Vegetation and Floral Propagation segment is engaged in the indoor propagation of vegetables and floral plants supplying fresh produce and ornamental plants to agricultural and retail customers. The segment operates controlled environment facilities that optimize yield and quality while minimizing resource use. Aurora’s propagation business leverages its expertise in horticulture to provide consistent supplies of vegetables such as lettuce and herbs and floral plants such as cut flowers to distributors and grocers.
Aurora Cannabis Inc. holds a leading market position in the medical cannabis sectors of Canada Germany the United Kingdom Poland and Australia and is regarded as one of the foremost producers in the European medical cannabis market. The company’s competitive advantages stem from its proprietary genetics and breeding program its regulatory expertise across multiple jurisdictions its European Union Good Manufacturing Practices certification and its scalable cultivation and distribution infrastructure. Aurora’s science leadership in cannabis genetics has yielded twenty six proprietary cultivars since June 2021 and continues to deliver new traits such as powdery mildew resistance that enhance crop quality and reduce cultivation costs. The company’s direct to patient model in Canada provides it with pricing power and margin advantages over the adult use segment while its international medical operations benefit from early mover status in several regulated markets.
Aurora Cannabis Inc. serves medical patients in Canada Germany the United Kingdom Poland and Australia and recreational adult use consumers in Canada. The company also supplies vegetables and floral plants to agricultural businesses and retail outlets and collaborates with distribution partners in its international medical markets. In Australia the company reaches patients through its subsidiary MedReleaf Australia which distributes medical cannabis products and has expanded sales into New Zealand. Aurora’s genetics and breeding outcomes are licensed to other Canadian licensed producers expanding the reach of its intellectual property beyond its own cultivation footprint.
Sector:Consumer StaplesSector rationaleThe company's primary revenue is derived from the production and sale of cannabis and cannabis derivative products to both medical patients and recreational consumers, which falls under the 'Cannabis' industry in Consumer Staples. Additionally, it operates a 'Vegetation and Floral Propagation' segment selling vegetables and floral plants to grocers and distributors, which aligns with 'Agricultural Products' also within Consumer Staples; therefore, no secondary sector is required as all business lines reside in the same sector.Industries:CannabisConsumer StaplesPrimaryAurora Cannabis produces, distributes, and sells medical and adult-use cannabis products, including oils and capsules, to patients and recreational consumers in Canada and international markets.Agricultural ProductsConsumer StaplesSecondaryThe company operates a Vegetation and Floral Propagation segment that sells vegetables, such as lettuce and herbs, and floral plants to agricultural and retail customers.Classified using BQ-MICSCIK: 0001683541
Investment Thesis
▲ Bull case
Aurora Cannabis is strategically positioned to capitalize on the accelerating global medical cannabis market through its unmatched GMP-certified manufacturing footprint, with approximately 90% of annual capacity in European and TGA-certified facilities—a regulatory moat that few competitors can replicate. This certification enables direct shipments to high-barrier markets like Germany and Australia, ensuring supply chain reliability and pricing power as reimbursement frameworks expand across the EU. Management’s focus on shifting the Australian product mix toward premium offerings, despite near-term margin pressure, reflects a disciplined long-term strategy to capture higher-value segments in a market projected by the Pennington Institute to reach $1 billion, where Aurora already holds the number two share. The divestment of the lower-margin plant propagation business (Bevo) and exit from select Canadian consumer cannabis markets are not merely cost-cutting moves but a reallocation of scarce, high-THC flower inventory to international medical channels, where gross margins remain robust at 69%—a differential that will directly boost consolidated profitability once fully executed. The newly established $100 million ATM equity program provides flexible, non-dilutive capital for accretive M&A or cultivation expansion in underserved markets like Switzerland, Austria, and France, where science-based regulatory frameworks are emerging and Aurora’s GMP credentials grant first-mover advantage. With over $154 million in cash and zero cannabis-related debt, the balance sheet offers a fortress-like foundation to weather short-term transitions while funding strategic investments that peers with leverage cannot match. Full-year guidance for global medical cannabis net revenue ($269M–$281M) and adjusted EBITDA ($52M–$57M) implies 5–10% annual growth, but this likely understates potential given the company’s market-leading share in Germany and Poland, ongoing facility expansions in Germany, and the untapped upside from premiumization in Australia—factors management did not emphasize during the call despite their transformative potential.
Aurora Cannabis is strategically positioned to capitalize on the accelerating global medical cannabis market through its unmatched GMP-certified manufacturing footprint, with approximately 90% of annual capacity in European and TGA-certified facilities—a regulatory moat that few competitors can replicate. This certification enables direct shipments to high-barrier markets like Germany and Australia, ensuring supply chain reliability and pricing power as reimbursement frameworks expand across the EU. Management’s focus on shifting the Australian product mix toward premium offerings, despite near-term margin pressure, reflects a disciplined long-term strategy to capture higher-value segments in a market projected by the Pennington Institute to reach $1 billion, where Aurora already holds the number two share. The divestment of the lower-margin plant propagation business (Bevo) and exit from select Canadian consumer cannabis markets are not merely cost-cutting moves but a reallocation of scarce, high-THC flower inventory to international medical channels, where gross margins remain robust at 69%—a differential that will directly boost consolidated profitability once fully executed. The newly established $100 million ATM equity program provides flexible, non-dilutive capital for accretive M&A or cultivation expansion in underserved markets like Switzerland, Austria, and France, where science-based regulatory frameworks are emerging and Aurora’s GMP credentials grant first-mover advantage. With over $154 million in cash and zero cannabis-related debt, the balance sheet offers a fortress-like foundation to weather short-term transitions while funding strategic investments that peers with leverage cannot match. Full-year guidance for global medical cannabis net revenue ($269M–$281M) and adjusted EBITDA ($52M–$57M) implies 5–10% annual growth, but this likely understates potential given the company’s market-leading share in Germany and Poland, ongoing facility expansions in Germany, and the untapped upside from premiumization in Australia—factors management did not emphasize during the call despite their transformative potential.
Aurora Cannabis faces significant execution risks in its Australian premiumization strategy, where management acknowledged anticipated near-term pressure on sales and gross profit during the transition from value-priced to core and premium products—a shift that could prolong margin compression if physician and patient adoption lags, especially given that most Australian sales currently remain concentrated in low-margin offerings. The company’s reliance on international medical cannabis for over 80% of net revenue exposes it to heightened regulatory volatility, as evidenced by evolving frameworks in Poland (telehealth restrictions) and potential changes in Germany’s telehealth cannabis policies, which could disrupt established distribution channels and increase compliance costs despite Aurora’s strong regulatory team. While the divestment of the Bevo plant propagation business removes a lower-margin segment, the reported $1.1 million inventory write-off and declining adjusted gross margin (from 40% to 16%) in that segment during Q3 signal deeper operational weaknesses in cultivation efficiency that may persist in retained assets or affect transition costs, undermining confidence in management’s ability to optimize complex agricultural operations. Adjusted SG&A increased 14.5% year-over-year to $35.8 million, driven by higher professional fees and expanding headcount in Europe and Australia—a trend that could erode profitability if revenue growth fails to keep pace, particularly as the company invests in premium market transitions without clear near-term margin improvement guidance. The free cash flow decline to $15.5 million from $27.4 million year-over-year, attributed to lower working capital recovery, raises concerns about the quality of earnings and the sustainability of cash generation, especially as the company prepares for potential M&A or capacity expansion via the ATM program, which could dilute shareholders if deployed accretively is not guaranteed. Finally, the full-year guidance for global medical cannabis revenue ($269M–$281M) implies only modest growth from the current run rate, suggesting the market may be overestimating the pace of international expansion, and the lack of specific timelines for profitability uplift from strategic exits creates uncertainty about when the reallocation of resources will translate into measurable financial benefits.
Aurora Cannabis faces significant execution risks in its Australian premiumization strategy, where management acknowledged anticipated near-term pressure on sales and gross profit during the transition from value-priced to core and premium products—a shift that could prolong margin compression if physician and patient adoption lags, especially given that most Australian sales currently remain concentrated in low-margin offerings. The company’s reliance on international medical cannabis for over 80% of net revenue exposes it to heightened regulatory volatility, as evidenced by evolving frameworks in Poland (telehealth restrictions) and potential changes in Germany’s telehealth cannabis policies, which could disrupt established distribution channels and increase compliance costs despite Aurora’s strong regulatory team. While the divestment of the Bevo plant propagation business removes a lower-margin segment, the reported $1.1 million inventory write-off and declining adjusted gross margin (from 40% to 16%) in that segment during Q3 signal deeper operational weaknesses in cultivation efficiency that may persist in retained assets or affect transition costs, undermining confidence in management’s ability to optimize complex agricultural operations. Adjusted SG&A increased 14.5% year-over-year to $35.8 million, driven by higher professional fees and expanding headcount in Europe and Australia—a trend that could erode profitability if revenue growth fails to keep pace, particularly as the company invests in premium market transitions without clear near-term margin improvement guidance. The free cash flow decline to $15.5 million from $27.4 million year-over-year, attributed to lower working capital recovery, raises concerns about the quality of earnings and the sustainability of cash generation, especially as the company prepares for potential M&A or capacity expansion via the ATM program, which could dilute shareholders if deployed accretively is not guaranteed. Finally, the full-year guidance for global medical cannabis revenue ($269M–$281M) implies only modest growth from the current run rate, suggesting the market may be overestimating the pace of international expansion, and the lack of specific timelines for profitability uplift from strategic exits creates uncertainty about when the reallocation of resources will translate into measurable financial benefits.